Busey Bank Trims Position in Edwards Lifesciences Co. (NYSE:EW)

Busey Bank trimmed its stake in Edwards Lifesciences Co. (NYSE:EW) by 9.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,885 shares of the medical research company’s stock after selling 788 shares during the period. Busey Bank’s holdings in Edwards Lifesciences were worth $584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the period. Peoples Bank KS bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth $40,000. Finally, JFS Wealth Advisors LLC lifted its stake in shares of Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on EW. Barclays boosted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Robert W. Baird decreased their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. The Goldman Sachs Group upped their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Truist Financial reissued a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Stock Up 2.8 %

Edwards Lifesciences stock opened at $73.15 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a market cap of $43.14 billion, a price-to-earnings ratio of 10.56, a price-to-earnings-growth ratio of 3.54 and a beta of 1.11. The business’s 50-day moving average price is $72.40 and its 200 day moving average price is $70.07. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock valued at $2,195,180 in the last 90 days. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.